LEXINGTON, Mass.--(BUSINESS WIRE)--Pulmatrix, a clinical stage biotechnology company discovering and developing a new class of therapies for the prevention, treatment and control of respiratory diseases, announced today results from two preclinical studies demonstrating that PUR118, the company’s novel, inhaled dry-powder therapeutic, was effective in reducing airway inflammation and exacerbation response in animal models of progressive respiratory diseases. The results were presented during oral and poster sessions on September 26 and 27, 2011, at the European Respiratory Society (ERS) Annual Congress in Amsterdam, Netherlands.
